Back to Journals » Substance Abuse and Rehabilitation » Volume 15

Transitioning Virtual-Only Group Therapy for Substance Use Disorder Patients to a Hybrid Model

Authors Oesterle TS , Bormann NL , Ochal DA, Arndt S, Breitinger SA

Received 17 January 2024

Accepted for publication 20 April 2024

Published 23 April 2024 Volume 2024:15 Pages 73—78

DOI https://doi.org/10.2147/SAR.S460024

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Rajendra D. Badgaiyan



Tyler S Oesterle,1,* Nicholas L Bormann,1,* Domenic A Ochal,2 Stephan Arndt,3,4 Scott A Breitinger1

1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; 2Mayo Clinic Alix School of Medicine, Rochester, MN, USA; 3Department of Psychiatry, University of Iowa, Iowa City, IA, USA; 4Department of Biostatistics, University of Iowa, Iowa City, IA, USA

*These authors contributed equally to this work

Correspondence: Nicholas L Bormann, Department of Psychiatry and Psychology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA, Tel +1 507 284 2088, Fax +1 507 284 4158, Email [email protected]

Purpose: Telehealth is associated with a myriad of benefits; however, little is known regarding substance use disorder (SUD) treatment outcomes when participants join group therapy sessions in a combination in-person and virtual setting (hybrid model). We sought to determine if treatment completion rates differed.
Patients and Methods: Policy changes caused by the COVID-19 pandemic created a naturalistic, observational cohort study at seven intensive outpatient (IOP) programs in rural Minnesota. Virtual-only delivery occurred 6/1/2020-6/30/2021, while hybrid groups occurred 7/1/2021-7/31/2022. Data was evaluated retrospectively for participants who initiated and discharged treatment during the study period. Participants were IOP group members 18 years and older who had a SUD diagnosis that both entered and discharged treatment during the 26-month period. A consecutive sample of 1502 participants (181– 255 per site) was available, with 644 removed: 576 discharged after the study conclusion, 49 were missing either enrollment or discharge data, 14 transferred sites during treatment, and 5 initiated treatment before the study initiation. Helmert contrasts evaluated the impact of hybrid group exposure.
Results: A total of 858 individuals were included. Data was not from the medical chart and was deidentified preventing specific demographics; however, the overall IOP sample for 2020– 2022, from which the sample was derived, was 29.8% female, and 64.1% were 18– 40 years of age. For completed treatment, hybrid group exposure relative to virtual-only had a univariate odds ratio of 1.88 (95% CI: 1.50– 2.41, p < 0.001). No significant difference was seen across IOP sites.
Conclusion: These results describe a novel hybrid group approach to virtual care for SUDs with outcome data not previously documented in the literature. While virtual treatment delivery can increase access, these results suggest a benefit is derived from including an in-person option. Further research is needed to identify how an in-person component may change dynamics and if it can be replicated in virtual-only models.

Keywords: substance-related disorders, telemedicine, group psychotherapy, comparative study, outcome assessment, health care

Introduction

Group therapy is a cornerstone of substance use disorder (SUD) treatment due to its effectiveness, practical design, and encouraging environment.1–3 Research has supported in-person group therapy in reducing substance use, improving social functioning, and decreasing co-occurring mental health symptoms.1,4 During the COVID-19 pandemic, many SUD programs transitioned to virtual groups.5 In 2015, a quarter of SUD treatment facilities offered telehealth services; by 2020 year-end, this increased to 58.6%.6

Virtual groups increase accessibility, provide greater anonymity, and are cost-effective.5 These factors may be particularly important for individuals in rural areas, working unconventional hours, or for whom transportation concerns impact treatment.7 However, internet connection and platform malfunction can disrupt virtual group flow and decrease engagement.5 Additionally, virtual groups may lack the social support that in-person groups provide.8 Little is known about how to best enhance outcomes in virtually delivered SUD treatment.5

Following 2020 COVID-19 restrictions, Mayo Clinic Health System (MCHS) transitioned outpatient SUD group-based treatment to virtual-only treatment. Due to a 20% census drop during this time and reports that some participants were dissatisfied with virtual groups, we converted group rooms into teleconference rooms (see Figure 1). Patients could attend in person and see and interact with their “virtual group” members through a conference camera and large-screen television. We call this a “hybrid” model as patients attended both in person and remotely. We gathered data on treatment completion for the purpose of quality improvement.

Figure 1 Hybrid group therapy set-up.

Notes: (A) Large flatscreen television displaying patients attending the group virtually. (B) Video conferencing camera located on a short table in the center of the room which includes built-in microphones, speakers and 2 cameras with panoramic views of the room. (C) Chairs evenly spaced for the counselor and the participants who joined in-person.

Materials and Methods

Design

Virtual-only groups occurred 6/1/2020-6/30/2021, while hybrid groups occurred 7/1/2021-7/31/2022. The hybrid period was pre-defined as 13 months, matching the duration of virtual-only delivery. Three cohorts based on delivery-type exposure were naturalistically formed: virtual-only, hybrid-only, and those experiencing both conditions (“dually-exposed”). Participant discharge status was the primary outcome, defined as completed treatment (discharged with medical advice) or premature discharge, which included discharge against medical advice (AMA) and staff-requested discharge (SRD). AMA categorization occurred when participants stopped attending or notified staff they were terminating treatment despite recommendations; SRD would occur due to violence, threats, or similar safety concerns. If a participant’s treatment spanned both virtual-only and hybrid groups, they were classified as dually-exposed.

Participants

Participants were enrolled in intensive outpatient (IOP) SUD treatment at 1 of 7 sites (median population <30,000) affiliated with MCHS. IOP is group-based (8–12 participants), delivered 9 hours weekly for approximately 3 months. The program is abstinence-based (does allow medication for addiction treatment and nicotine/tobacco) and encourages medication management for co-occurring disorders with providers available. Participants complete treatment after sustained abstinence, completed assignments and consistent group attendance/participation. Referrals occur through social workers, other treatment programs, drug courts, and self-referral. Inclusion criteria were 18 years or older, a Diagnostic and Statistical Manual of Mental Disorders fifth edition SUD,9 and enrolled in a MCHS IOP site. Exclusion criteria were if treatment began prior to transition to virtual-only or if discharged after the predetermined study end. Due to deidentification, specific sample characteristics are unavailable. However, Table 1 displays IOP demographics for 2020–2022, which is the population the study cohort is from.

Table 1 Mayo Clinic Health System Intensive Outpatient Program Participanta

Statistical Analysis

Helmert contrasts evaluated the effects of hybrid delivery. Virtual-only participants were contrasted with participants either in hybrid-only or dually-exposed (HC1). Then, hybrid-only participants were contrasted with dually-exposed participants (HC2). Logistic regression assessed the effect of group (virtual-only, hybrid-only, dually-exposed) on outcome (discharge status) while initially controlling for treatment site however it was removed due to non-significance. Two degrees of freedom (df) (ie, 3 groups) log-likelihood chi-square test compared differences across groups. Odds ratio confidence interval and p-value were obtained through the described logistic regression.

Analyses were performed using R 4.2.110 with packages car, dplyr, and lubridate. The MCHS IRB deemed this study exempt due to retrospectively analyzed deidentified data originally collected for quality improvement purposes. Patient informed consent was therefore waived by the IRB. This study complies with the Declaration of Helsinki.

Results

Originally there were 1502 participants across 7 sites (181–255 participants per site). After inclusion/exclusion criteria, 644 participants were removed due to the following:

  • 343 discharged after the predefined study endpoint.
  • 233 entered during the hybrid period, however, were in treatment at time of analysis and therefore had no discharge status.
  • 49 were missing enrollment or discharge dates.
  • 14 transferred sites during the study.
  • 5 began treatment prior to the transition to virtual-only groups.

The IOP sample was predominantly White, male, and 18 to 40 years old (Table 1). Descriptive measures are seen in Table 2. More participants were exposed to hybrid delivery due to the naturalistic study design. HC1 displayed an advantage for hybrid-delivery relative to exclusively virtual-only for completed treatment with OR = 1.88 (95% CI: 1.5–2.37). HC2 displayed an advantage to those dually-exposed relative to those exclusively in the hybrid model for completed treatment with OR = 1.99 (95% CI: 1.65–2.41). For logistic regression, both HC1 (estimate: 0.631, SE: 0.117, p < 0.0001) and HC2 were highly significant (estimate: −0.686, SE: 0.097, p < 0.0001). Likelihood ratio tests showed a significant difference across both HC1 (χ2 = 31.03, df = 1, p-value < 0.0001) and HC2 (χ2=53.38, df = 1, p-value < 0.0001).

Table 2 Descriptive Measures

Discussion

Although many studies have reported benefits with virtual group therapy, this is the first to our knowledge that suggests incorporating an in-person option may enhance those services for SUD treatment. While telehealth increases access and is rapidly scalable,6,11 it remains unclear how removing the in-person component may impact group dynamics such as therapeutic alliance (TA), cohesiveness and overall satisfaction.8,12

The dually-exposed group had a high treatment completion rate, which may reflect a benefit derived following the intervention change. Rates of completed treatment were low for the sample, however, with approximately one-third of all participants meeting that criterion. An analysis of the 2011 Treatment Episode Data Set: Discharge (TEDS-D) database found that 52% of individuals discontinued in person outpatient SUD treatment.13 COVID-19 may have contributed to our studies lower rates of completed treatment, as postponing or avoiding medical care during the pandemic became increasingly common.14

Bronson et al reviewed 122 studies, including nearly 200,000 participants, and found risk factors for SUD treatment discontinuation included low rates of TA.15 TA, or the participants reported connection to their counselor/group facilitator, has been shown to be an important factor across psychotherapy interventions.16 It is unclear how differing SUD treatment delivery may impact TA. Drawing from non-SUD literature, in a cohort of 291 Spanish adults with primarily affective disorders seeking individual therapy, those engaging virtually reported delayed growth in TA as compared to those treated in-person.17 Specific to group therapy, overall cohesiveness of the group, or the level of connection between group members, may also be impacted by virtual groups. This literature is limited however, with previous small studies (samples of 35 and 58) reporting either lower levels of group cohesion18 or increased difficulty connecting with other group members.19

Participant autonomy for how one received treatment may have also been important. The hybrid model allowed participants to express a choice in how they received treatment. This may have enhanced a pro-recovery environment.20 The loss of free will, such as in compulsory, or court-mandated treatment, may be effective for some, however existing evidence calls into question its long-term effectiveness.21 Stigma related to SUDs is also diverse in construct22 with a longitudinal impact.23 Not mandating a certain treatment approach may have allowed hybrid participants to tolerate this with less difficulty.

The interpretation of these results does not question the utility of telehealth. Rather, they propose the thoughtful use of virtual visits in conjunction with in-person options rather than an all-or-none approach. The Consolidated Appropriations Act extended the flexibility afforded to Medicare recipients following COVID-19 for receiving telehealth services through 2024.24 While recommendations vary across healthcare and specialties regarding how often to see patients in-person, further research is needed on the long-term implications of exclusively virtual care, particularly in a group setting. This research may identify what an in-person component adds, and if this could be replicated somehow in virtual-only care.

Limitations

Deidentification prevented controlling for demographics and specific SUDs, which limits generalizability. To maximize data, we grouped hybrid-only and dually-exposed in the comparison with virtual-only; this may have introduced bias, however is consistent with Helmert contrasts. Additionally, data does not exist for hybrid groups at the participant level regarding how often an individual joined virtually versus in-person. Our experience was that there was a fairly even mix of participants who always came in person, some who always attended virtually and those who’s attendance would vary; however, we do not have data to quantify this observation. Therefore, the intervention was “exposure to the hybrid model” and not a reflection on how each participant individually attended the hybrid groups. As this was a naturalistic study, virtual groups occurred earlier and hybrid subsequently later in time. Environmental factors like changes in COVID restrictions may have increased people’s willingness to stay in treatment regardless of treatment delivery options. Finally, as these sites are in a rural setting, it is unclear how these results may translate to a metropolitan-based sample.

Conclusion

This is the first report in the scientific literature to show that a hybrid group model that includes a combined in-person and virtual treatment option is not worse and may enhance rates of completed treatment relative to virtual-only SUD groups. Future prospective studies are needed to evaluate the potential enhancement of virtual delivery by the incorporation of an in-person option. While telehealth has many advantages, in-person options may help augment the treatment experience.

Funding

Dr. Oesterle was supported by National Institutes of Health [R18 HS029774-01], the Terrance and Bette Noble Foundation, and the Mayo Clinic Kern Center for the Science of Health Care Delivery.

Disclosure

The authors report no conflicts of interest in this work.

References

1. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry. 1995;152(11 Suppl):1–59. doi:10.1176/ajp.152.11.1

2. Lopez G, Orchowski LM, Reddy MK, Nargiso J, Johnson JE. A review of research-supported group treatments for drug use disorders. Subst Abuse Treat Prev Policy. 2021;16(1):51. doi:10.1186/s13011-021-00371-0

3. Weiss RD, Jaffee WB, de Menil VP, Cogley CB. Group therapy for substance use disorders: what do we know? Harv Rev Psychiatr. 2004;12(6):339–350. doi:10.1080/10673220490905723

4. de Andrade D, Elphinston RA, Quinn C, Allan J, Hides L. The effectiveness of residential treatment services for individuals with substance use disorders: a systematic review. Drug Alcohol Depend. 2019;201:227–235. doi:10.1016/j.drugalcdep.2019.03.031

5. Oesterle TS, Kolla B, Risma CJ, et al. Substance use disorders and telehealth in the COVID-19 pandemic era: a new outlook. Mayo Clin Proc. 2020;95(12):2709–2718. doi:10.1016/j.mayocp.2020.10.011

6. Alvarado HA Telemedicine services in substance use and mental health treatment facilities. The CBHSQ Spotlight; 2021. Available from: https://www.samhsa.gov/data/report/telemedicine-services. Accessed April 22, 2024.

7. Barak K, Hen L, Boniel-Nissim M, Shapira N. A comprehensive review and a meta-analysis of the effectiveness of Internet-based psychotherapeutic interventions. J Technol Human Serv. 2008;26(2–4):109–160. doi:10.1080/15228830802094429

8. Hedman E, Ljotsson B, Kaldo V, et al. Effectiveness of Internet-based cognitive behaviour therapy for depression in routine psychiatric care. J Affect Disord. 2014;155:49–58. doi:10.1016/j.jad.2013.10.023

9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.

10. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022.

11. Shaver J. The state of telehealth before and after the COVID-19 pandemic. Prim Care. 2022;49(4):517–530. doi:10.1016/j.pop.2022.04.002

12. Riper H, Andersson G, Christensen H, Cuijpers P, Lange A, Eysenbach G. Theme issue on e-mental health: a growing field in internet research. J Med Internet Res. 2010;12(5):e74. doi:10.2196/jmir.1713

13. Stahler GJ, Mennis J, DuCette JP. Residential and outpatient treatment completion for substance use disorders in the U.S.: moderation analysis by demographics and drug of choice. Addict Behav. 2016;58:129–135. doi:10.1016/j.addbeh.2016.02.030

14. Czeisler ME, Marynak K, Clarke KEN, et al. Delay or Avoidance of medical care because of COVID-19-related concerns - United States. MMWR Morb Mortal Wkly Rep. 2020;69(36):1250–1257. doi:10.15585/mmwr.mm6936a4

15. Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013;33(8):1010–1024. doi:10.1016/j.cpr.2013.07.007

16. Fluckiger C, Del Re AC, Wampold BE, Horvath AO. The alliance in adult psychotherapy: a meta-analytic synthesis. Psychotherapy. 2018;55(4):316–340. doi:10.1037/pst0000172

17. Mercadal Rotger J, Cabre V. Therapeutic alliance in online and face-to-face psychological treatment: comparative study. JMIR Ment Health. 2022;9(5):e36775. doi:10.2196/36775

18. Lopez A, Rothberg B, Reaser E, Schwenk S, Griffin R. Therapeutic groups via video teleconferencing and the impact on group cohesion. Mhealth. 2020;6:13. doi:10.21037/mhealth.2019.11.04

19. Sugarman DE, Busch AB, McHugh RK, et al. Patients’ perceptions of telehealth services for outpatient treatment of substance use disorders during the COVID-19 pandemic. Am J Addict. 2021;30(5):445–452. doi:10.1111/ajad.13207

20. Williamson L. Creating an ethical culture to support recovery from substance use disorders. J Med Ethics. 2020;47(12):e9. doi:10.1136/medethics-2020-106661

21. Werb D, Kamarulzaman A, Meacham MC, et al. The effectiveness of compulsory drug treatment: a systematic review. Int J Drug Policy. 2016;28:1–9. doi:10.1016/j.drugpo.2015.12.005

22. Kulesza M, Larimer ME, Rao D. Substance use related stigma: what we know and the way forward. J Addict Behav Ther Rehabil. 2013;2(2). doi:10.4172/2324-9005.1000106

23. Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav. 1997;38(2):177–190. doi:10.2307/2955424

24. HHS fact sheet: telehealth flexibilities and resources and the COVID-19 public health emergency. U.S. Department of Health and Human Services; 2023. Available from: https://www.hhs.gov/about/news/2023/05/10/hhs-fact-sheet-telehealth-flexibilities-resources-covid-19-public-health-emergency.html#:~:text=Medicare%20and%20Telehealth&text=The%20Consolidated%20Appropriations%20Act%2C%202023%2C%20extended%20many%20Medicare%20telehealth%20flexibilities,than%20only%20in%20rural%20areas. Accessed August 26, 2023.

Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.